Lyra Therapeutics (LYRA) Non-Current Deffered Revenue (2021 - 2025)
Historic Non-Current Deffered Revenue for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $11.9 million.
- Lyra Therapeutics' Non-Current Deffered Revenue changed 0.0% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $11.9 million for FY2024, which is 225.77% down from last year.
- As of Q3 2025, Lyra Therapeutics' Non-Current Deffered Revenue stood at $11.9 million, which was down 0.0% from $11.9 million recorded in Q2 2025.
- Lyra Therapeutics' 5-year Non-Current Deffered Revenue high stood at $14.1 million for Q4 2022, and its period low was $1.9 million during Q4 2021.
- For the 5-year period, Lyra Therapeutics' Non-Current Deffered Revenue averaged around $10.6 million, with its median value being $11.9 million (2024).
- Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first surged by 63089.3% in 2022, then tumbled by 1378.84% in 2023.
- Over the past 5 years, Lyra Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $1.9 million in 2021, then surged by 630.89% to $14.1 million in 2022, then fell by 13.79% to $12.1 million in 2023, then dropped by 2.26% to $11.9 million in 2024, then changed by 0.0% to $11.9 million in 2025.
- Its last three reported values are $11.9 million in Q3 2025, $11.9 million for Q2 2025, and $11.9 million during Q1 2025.